Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Counterregulatory responses to postprandial hypoglycemia after Roux-en-Y gastric bypass

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Primary care physician decision making regarding referral for bariatric surgery: a national survey

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Postprandial hyperinsulinemic hypoglycemia after Roux-en-Y gastric bypass: an update

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effects of endogenous GIP in patients with type 2 diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: Postbariatric hypoglycemia (PBH) is a potentially serious complication after Roux-en-Y gastric bypass (RYGB), and impaired counterregulatory hormone responses have been suggested to contribute to the condition. Objectives: We evaluated counterregulatory responses during postprandial hypoglycemia in individuals with PBH who underwent RYGB. Setting: University hospital. Methods: Eleven women with documented PBH who had RYGB underwent a baseline liquid mixed meal test (MMT) followed by 5 MMTs preceded by treatment with (1) acarbose 50 mg, (2) sitagliptin 100 mg, (3) verapamil 120 mg, (4) liraglutide 1.2 mg, and (5) pasireotide 300 μg. Blood was collected at fixed time intervals. Plasma and serum were analyzed for glucose, insulin, glucagon, epinephrine, norepinephrine, pancreatic polypeptide (PP), and cortisol. Results: During the baseline MMT, participants had nadir blood glucose concentrations of 3.3 ±.2 mmol/L. At the time of nadir glucose, there was a small but significant increase in plasma glucagon. Plasma epinephrine concentrations were not increased at nadir glucose but were significantly elevated by the end of the MMT. There were no changes in norepinephrine, PP, and cortisol concentrations in response to hypoglycemia. After treatment with sitagliptin, 8 individuals had glucose nadirs <3.2 mmol/L (versus 4 individuals at baseline), and significant increases in glucagon, PP, and cortisol responses were observed. Conclusions: In response to postprandial hypoglycemia, individuals with PBH who underwent RYGB only had minor increases in counterregulatory hormones, while larger hormone responses occurred when glucose levels were lowered during treatment with sitagliptin. The glycemic threshold for counterregulatory activation could be altered in individuals with PBH, possibly explained by recurrent hypoglycemia.

OriginalsprogEngelsk
TidsskriftSurgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
Vol/bind17
Udgave nummer1
Sider (fra-til)55-63
Antal sider9
ISSN1550-7289
DOI
StatusUdgivet - jan. 2021

Bibliografisk note

Copyright © 2020 American Society for Bariatric Surgery. Published by Elsevier Inc. All rights reserved.

ID: 61115032